1 / 11

Claudin -low/Basal

a. Figure 1. b. HER2-amplified. Claudin -low/Basal . Luminal. e. c. d. f. *. *. *. *. Figure 2. d. b. c. a. *. *. f. e. g. P<0.001. P=0.56. P=0.009. a. Figure 3. b. MCF7 growth with early treatment. MCF7 growth with late treatment. d. c. f. e. g. Figure 4. *.

patty
Télécharger la présentation

Claudin -low/Basal

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. a Figure 1 b HER2-amplified Claudin-low/Basal Luminal e c d f * * * *

  2. Figure 2 d b c a * * f e g P<0.001 P=0.56 P=0.009

  3. a Figure 3 b MCF7 growth with early treatment MCF7 growth with late treatment d c f e g

  4. Figure 4 * * c d a b

  5. Figure 5 c b d Late treatment * * * Early treatment ALDH HER2 a Fat pad Tibia h g e f * * k j i HER2 ALDH1 Tibia control Tibia Trastuzumab

  6. Figure 6 Bone b a Primary Luminal HER2-amplified d c Metastatic-Advanced Clinical Endpoint Tumor Regrassion Micrometastatic-Adjuvant Clinical Endpoint Reduction in Tumor Recurrence Breast Tumors HER2+++ (Amplified) YES YES HER2+ or ++ (Non-amplified) NO YES Basal HER2- ER- NO NO

  7. Supplementary 1 a b

  8. MCF7 ZR75-1 Supplementary 2 * a b *

  9. Supplementary 3 b a

  10. Supplementary 4 MCF7_Her2 Isotype control Coculture+Denosumab_HER2 a a 0.1% 26.13% Osteocyte Coculture_HER2 b b HER2 HER2 shHER-2 shHER-2 shVector shVector Actin Actin 44.9% 30.13%

  11. Supplementary 5 a b Luminal HER2 amplified

More Related